The METEOR trial examined AstraZenecas Crestor (rosuvastatin) in patients with early signs of atherosclerosis. C&I notes that because the METEOR study did not show regression of atherosclerosis...
Recent stories in C&I have appeared to cast doubt on the safety of bisphenol-A: Chemical conflicts of interest (C&I 2007, 5, 4) and Unsafe levels of BPA found in cans (C&I 2007, 6, 11). H...
Gerald V Coles ,Victoria, Australia In one of the important ‘climate change’ letters in recent issues (C&I 2007, 12, 18), Trevor Kletz asks a very valid question about the CO2 production from human p...
Werner Koerbitz , chairman, Austrian Biofuels Institute Thank you for your excellent analysis in ‘Who’s winning the PR battle?’ (C&I 2007, 11, 4). Having been in the business of biofuels, and of biodi...
Brian Wood , Glasgow, Scotland I was interested in the feature on improvements in desalination technology (C&I 2007, 15, 24). Some years ago someone with, presumably, not much to do one afternoon, wor...
Pete Laity,Cambridge University, UK I have just read – with some amazement and considerable anger – a collection of lies, half-truths and blatant misinterpretations, in the form of a letter from Arch...
Bryan Reuben, London South Bank University The recent leader in C&I was headed ‘Is anybody out there?’ (C&I 2007, 13, 4). If you mean the British chemical industry, the answer is an unequivocal no. I...